FOXF2 CRISPR/Cas9 KO Plasmid (m): sc-420374

Overview

Forkhead box F2 (Foxf2) encodes the transcription factor FOXF2, a mesenchyme-enriched regulator of developmental gene programs that shape tissue patterning, extracellular matrix organization, and epithelial–mesenchymal signaling. In mouse, Foxf2 activity contributes to organogenesis and stromal differentiation by controlling transcriptional networks downstream of morphogen cues, including pathways associated with TGF-β/BMP signaling, Wnt modulation, and cytoskeletal/ECM remodeling. Dysregulated FOXF2-dependent transcription has been linked in the literature to altered fibroblast behavior, aberrant tissue architecture, and changes in barrier and vascular-associated stromal compartments, supporting its relevance to disease-relevant remodeling phenotypes. As a node in developmental and stromal gene regulation, Foxf2 is frequently studied in contexts such as fibrosis-like responses, tumor–stroma interactions, and developmental anomalies in mouse models.

FOXF2 CRISPR/Cas9 KO Plasmid (m) is a pool of plasmids designed for targeted disruption of the Foxf2 gene in mouse cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the Foxf2 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.

The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the Foxf2 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish FOXF2 protein expression.

This CRISPR knockout system enables efficient generation of Foxf2-deficient cell models for investigation of FOXF2 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.

Key Features

• sgRNAs targeting Foxf2 exon(s) critical for FOXF2 function
• Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
• GFP reporter for identification of transfected cells
• Pool of plasmids targeting multiple Foxf2 genomic sites to improve knockout efficiency
• Compatible with delivery by transfection

Design Variants

CRISPRs +/- HDRs

• gRNAs encoded by FOXF2 CRISPR/Cas9 KO Plasmid (m) and FOXF2 CRISPR/Cas9 KO Plasmid (m2) target distinct sites within the Foxf2 locus. One or both targeting designs may be available. See Related Products for availability.
• HDR donor constructs encoded by FOXF2 HDR Plasmid (m) and FOXF2 HDR Plasmid (m2) contain a puromycin resistance cassette and an RFP reporter flanked by Foxf2 homology arms to support homology-directed repair at defined Foxf2 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.

For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.